Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo Controlled, Phase IIA Study to Assess the Effect on Gastroesophageal Reflux Disease (GERD) Symptoms, Pharmacokinetics, Safety and Tolerability of 4 Weeks Treatment With AZD3355 65 mg Bid as add-on Treatment to a Proton Pump Inhibitor (PPI) in Patients With an Incomplete Response to PPI.
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
Age
17 - 70 years
Sex
ALL
Healthy Volunteers
No
Research Site
Adelaide, Australia
Research Site
Brussels, Belgium
Research Site
Eupen, Belgium
Research Site
Wilrijk, Belgium
Research Site
Alès, France
Research Site
Angers, France
Research Site
Bordeaux, France
Research Site
Lyon, France
Research Site
Nantes, France
Research Site
Cologne, Germany
Start Date
November 1, 2006
Primary Completion Date
June 1, 2007
Completion Date
June 1, 2007
Last Updated
March 18, 2013
244
ACTUAL participants
AZD3355
DRUG
Lead Sponsor
AstraZeneca
NCT07344935
NCT07179250
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT01940185